Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CLM-103 / CellabMed
MAGIC-I, NCT05540873: A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma	Recruiting	1	18	RoW	YYB-103	CellabMED	Recurrent Malignant Glioma	02/24	04/24
MT-026 / Suzhou Maximum Bio-tech
SJWKtumor001, NCT05752877: Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma	Recruiting	N/A	12	RoW	Targeted IL-13 Rα2 UCAR-T cell injection, Targeted B7-H3 UCAR-T cell injection	Second Affiliated Hospital of Soochow University, Soochow T-Maximun Biotechnology Co. LTD	Advanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy	04/26	04/26
SNC109 / Shanghai Simnova Bio
NCT05868083: The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma	Recruiting	1	16	RoW	SNC-109 CAR-T Cells	Shanghai Simnova Biotechnology Co.,Ltd., Chinese PLA General Hospital	Recurrent Glioblastoma Multiforme	05/24	08/24
NCT06616727: The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM	Enrolling by invitation	1	50	RoW	SNC109	Shanghai Simnova Biotechnology Co.,Ltd.	Recurrent Glioblastoma Multiforme (GBM)	12/24	12/26